Friday, 3 April 2020

Gestational Trophoblastic Disease Market Value Share, Supply Demand, Share And Value Chain 2019

Market Scenario:
Gestational trophoblastic disease (GTD) is a cluster of rare tumors that include abnormal growth of cells inside a woman's uterus. It arises from placental trophoblastic tissue and is characterized by β-subunit of human chorionic gonadotrophin (β HCG). The increasing prevalence of risk factors such as smoking, sexually transmitted diseases (STD), history of miscarriages, and high maternal age are expected to fuel the growth of the market during the forecast period. Rise in ectopic pregnancies is also a significant factor which causes GTD. According to the National Center for Biotechnology Information (NCBI), the risk of ectopic pregnancy is 20 times higher in women who smoke. On the other hand, high risks of recurrence and complications that may occur after the therapy and treatment procedure may hinder the growth of the market during the forecast period.
The global gestational trophoblastic disease treatment market is currently dominated by many market players. The key players in the market are involved in new product launches and strategic partnerships to strengthen its market position. For instance, in September 2018, Novartis AG entered into a license and collaboration agreement with Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company which develops therapies for cancer and degenerative diseases in Greater China.
Competitive Landscape:
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals PLC
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Antares Pharma
  • Mylan N.V.
  • Novartis AG
  • BP Pharmaceuticals Laboratories Company
  • Fresenius Kabi AGAccord Healthcare, Inc.
  • Eli Lilly and Company
  • Sanofi
  • Bayer AG
  • Amgen Inc.
  • Merck
Segmentation:The global gestational trophoblastic disease market has been segmented into type, treatment, and end user.
The market, on the basis of type, has been segmented into a hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumor, epithelioid trophoblastic tumor, and others.
The market, based on the hydatidiform mole, has been further segmented into a complete, partial and invasive mole. The market, based on hydatidiform mole is expected to hold the largest share as it is the most common form of the gestational trophoblastic disease,  whereas choriocarcinoma is projected to be the fastest-growing market as the incidence rate of this form is increasing steadily according to a journal published by National Center for Biotechnology Information.
The market, by treatment, has been segmented into surgery, chemotherapy, suction dilation and curettage (D&C), and radiation therapy.
The market, based on surgery, has been sub-segmented into an abdominal hysterectomy and vaginal hysterectomy.
The market, by end user, has been segmented into hospital and clinics, diagnostic centers, and others.
The market has been segmented regionally into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The gestational trophoblastic disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European gestational trophoblastic disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The gestational trophoblastic disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The gestational trophoblastic disease market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Geographically, the Americas is projected to dominate the global gestational trophoblastic disease market owing to an increased awareness about the disease and favorable reimbursement scenario. Also, the rise in a number of marketing approvals, as well as product approvals in the field of oncology drive the market growth.
Europe is expected to hold the second largest position in the global gestational trophoblastic disease market. The market growth in this region is attributed to the availability of funds for research and an increasing healthcare expenditure.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.
On the other hand, the Middle East and Africa has the least share of the market. This is due to the stringent government regulations and lack of technical expertise in the treatment of the disease.
Posted by at No comments:

Endovascular Aneurysm Repair Devices Market Dynamics, Forecast, Analysis And Supply Demand 2019

Market Scenario

Global endovascular aneurysm repair devices market is likely to grow significantly over the forecast period. It is estimated that the global endovascular aneurysm repair devices market is expected to record a CAGR ~ 6.4 % during the forecast period of 2018 to 2023. The weakening and bulging of the aorta is called aortic aneurysm. The bulging can cause a leak that spills blood into the body. It can direct the blood flow away from the organs and tissues, causing severe complications, such as kidney damage, heart attacks, stroke, and even death. Thus, endovascular repair can be done by placing a stent-graft in an aneurysm through a small hole in the blood vessels in the groin area.
Numerous factors such as reduced recovery times, low-cost hospitalization charges, and technological advancements in repair devices are expected to drive the growth of the market. For instance, in March 2017, Terumo Corporation completed the acquisition of Bolton Medical, Inc. with the acquired company being a leading innovator in thoracic and abdominal stent graft systems, Terumo Corporation aimed to strengthen its growth in vascular graft segment.
However, stringent government regulation, the preferable alternative of open surgery and various complications such as endoleaks and infections may hamper the market growth during the assessment period.
Segmentation
The global endovascular aneurysm repair devices market has been segmented into indication, site, anatomy, and products.
The market, on the basis of indication, has been segmented into the abdominal aortic aneurysm, thoracic aortic aneurysm and others.
The market, based on thoracic aortic aneurysm, has been further segmented into ascending aortic aneurysm, descending aortic aneurysm, thoracoabdominal aortic aneurysm, and thoracic arch aortic aneurysm.
The market, on the basis of the site, has been segmented into infrarenal and pararenal.
The market, based on pararenal site, has been sub-segmented into juxtarenal and suprarenal.
The market, on the basis of anatomy, has been segmented into traditional and complex.
The market, on the basis of products, has been segmented into percutaneous EVAR, fenestrated EVAR, aortic stents and TAA grafts, and others.
Key players
Cardiatis SA, Cardinal Health, Cook Medical LLC, Endologix, INC., Jotec GmbH, Medtronic plc, Terumo Corporation, W. L. Gore & Associates, Inc., BiFlow Medical Ltd, Boston Scientific Corporation, Braile Biomédica, Endoluminal Sciences Pty Ltd, Endospan Ltd., Getinge AB, and Lemaitre Vascular Inc. are some of the key players in the global endovascular aneurysm repair devices market.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The endovascular aneurysm repair devices market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European endovascular aneurysm repair devices market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The endovascular aneurysm repair devices market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The endovascular aneurysm repair devices market in the Middle East and Africa has been segmented into the Middle East, and Africa.
The Americas is expected to dominate the global endovascular aneurysm repair devices market owing to increasing geriatric population, and well-developed healthcare sector. With the increase in the geriatric population, the prevalence of aneurysms is also expected to rise. The Centers for Disease Control and Prevention (CDC) ranks abdominal aortic aneurysm as one of the top 15 causes of mortality in the United States, but only for those between 85 and 89 years. According to the Centers for Disease Control and Prevention, aortic aneurysms were the primary cause of 9,863 deaths in 2014 in the US.
Europe is expected to hold the second largest position in the global endovascular aneurysm repair devices market. The market growth in this region is attributed to the growing prevalence of aneurysms, availability of funds for research, and favorable reimbursement scenario.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to the growing government initiatives for the healthcare sector.
Posted by at No comments:

Distraction Osteogenesis Devices Market Up To 2023: Top Companies, Growth Factors Details And Regional Overview By Types & Application

Market Scenario:
Global Distraction Osteogenesis Devices Market study by MRFR asserts, the market is expected to grow significantly over the forecast period. Distraction osteogenesis is the biological process of the new bone formation between bone segments which are gradually separated by incremental traction.  
Numerous factors such as advancements in distractor devices such as miniaturized internal and external devices, easily placeable and easy handling are expected to drive the growth of the market. For instance, In May 2018, DePuy Synthes, a part of the Johnson & Johnson Medical Devices Companies, announced an exclusive agreement in the US between DePuy Synthes Sales, Inc. and Prosidyan to promote the Fibergraft family of products, a line of synthetic bone graft materials which are ultra-porous, designed for ease of use, and have been engineered for ideal resorption in clinical use during spine fusion surgery. By adding Fibergraft to its offerings, DePuy Synthes will further enhance the company’s portfolio of biomaterials and distractors.
Moreover, various risks such as failure to follow the distraction protocol and damages to nerves hamper the market growth during the assessment period.
Key players
Johnson & Johnson Services, Inc., Zimmer Biomet Holdings, Inc., Stryker Corporation, KLS Martin Group, Osteomed, Acumed LLC, Jeil Medical Corporation, Ningbo Cibei Medical Treatment Appliance Co., Ltd. Ortho Max Manufacturing Company Pvt. Ltd., Ortho Care and Titamed are some of the key players in the global distraction osteogenesis devices market.
Segmentation
The Global Distraction Osteogenesis Devices Market has been segmented into device type, age, application, and end-user.
The market, based on device type, has been segmented into mandibular distraction devices, palatal distraction devices, alveolar distraction devices, craniofacial distraction devices, Lefort distraction devices, small bone distraction devices, and others. The market, based on craniofacial distraction devices, has been further segmented into external and internal distractors. The market, based on external distractors is further classified into unidirectional distractors, bidirectional distractors, and multiplanar distractors whereas the market, based on, internal distractors can be classified into tooth-borne distractors, bone-borne distractors, and hybrid distractors. The market, by age, has been segmented into pediatrics and adults. The market, by application, has been segmented into dentistry, podiatry, orthopedics, and others. The market, by end-user, has been segmented into hospitals, orthopedic clinics, and others.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Distraction Osteogenesis Devices Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European distraction osteogenesis devices market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Distraction Osteogenesis Devices Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The distraction osteogenesis devices market in the Middle East & Africa has been segmented into the Middle East and Africa.
Geographically, North America is expected to dominate the global distraction osteogenesis devices market owing to increasing number of procedures for treating facial abnormalities in the US. Also, most of the key players have their research and development teams working in this field in the US which in turn increases the awareness among the people about the technique in this region.
The European market is expected to be the second-largest due to increase in initiatives taken by public and private organizations in this field.

Browse More Report Details @
Posted by at No comments:

Palliative Care Market To Observe Strong Development By 2019

Global Palliative Care Market, Type (Private Resident Care, Hospital Inpatient Care, Nursing Home and Residential Facility Center, and Others), by Application (Cancer, Kidney Failure, and Others), by End-User (Hospitals, Palliative Care Centers, and Others) Forecast to 2023
Market Scenario 
Palliative care helps to improve the quality of life of patients and their families facing the problems of serious illness. The main focus of Palliative care is to provide relief from symptoms and stress of a serious illness. Their main goal is to improve the quality of life for both the patient and the family. Palliative care treats people living with a serious illness such as cancer, cardiac diseases such as congestive heath failure, kidney failure, Alzheimer’s and many more. It improves the quality of life of the patient and supports the primary physician, patient, and family. In last 15 years, the Palliative care market has a stunning growth and the factors that have led to the growth of this market are growing the aging population, increase in chronic life-threatening disease, initiative taken by the government and non- profit organization, and rise in government funding.  
Global Palliative Care market is expected to grow during the forecast period at a CAGR ~8.1 %.
Increasing incidence of diseases such as cancer, cardiovascular and infective disease are some of the drivers responsible for the growth of global palliative care market. Other factors such as a growing number of palliative care centers worldwide, expanding aging demographics, increasing number of qualified physicians for palliative care are responsible for the rise in the global palliative market. The main object of palliative care is to enhance personal satisfaction for both the patient and family. This palliative care can be provided at any age and at any phase in a genuine ailment and can be furnished alongside remedial treatment.
However, the high cost of treatment, misuse of funding and lack of awareness are some of the factors which are hampering the growth of the market during the forecast period.
But the high cost of treatment, less private or public funding to hospital facilities and other medical centers can be a major restraint for the growth of the global palliative care market trends.
Key Players
  • Vitas Healthcare Corporation
  • Skilled Healthcare Group Incorporated
  • Sunrise Senior Living LLC
  • Kindred Healthcare Incorporated
  • Gentiva Health Services Incorporated
  • Home Instead Senior Care Incorporated
  • Amedisys Incorporated
  • Genesis HealthCare Corporation
Segmentation
The Global Palliative Care Market is segmented into types such as private residence care, hospice inpatient care, hospital inpatient care, nursing home and residential facility care and others. On the basis of application, the market is further segmented into cancer, cardiac diseases such as congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), kidney failure, Alzheimer’s, Parkinson’s, Amyotrophic Lateral Sclerosis (ALS) and many more. On basis of end-user, the market is further segmented into hospitals, home care settings, palliative care centers, long-term care centers & rehabilitation centers.
Regional Analysis
In terms of market value, North America will dominate the Palliative care market during the forecast period. Increasing incidences of life-threatening illness such as cancer, cardiovascular diseases, Alzheimer’s disease, kidney failure, chronic obstructive pulmonary disease and many more are some of the factors which are responsible for the growth of the market during the forecast period. In 2015 on average 90 % of US hospitals containing 300 beds or more provide Palliative care services to their patients. This has led to the growth of the market in coming years. The European market is expected to be the second-largest Palliative care market. The market growth in this region can be attributed to government funding and support of the healthcare sector coupled with increasing research and development. Moreover, a growing number of Palliative care centers worldwide, extending application for homecare, increasing number of qualified physicians for Palliative care center and expanding aging demographics are some of the factors responsible for the rise in the global Palliative care market. Asia-Pacific is expected to be the fastest-growing Palliative care market during the forecast period owing to the increasing prevalence of cardiac diseases, rising investments in healthcare, increasing geriatric population, and expansions by market players in the region. Asia-Pacific is giving the strong competition in the global Palliative care market by producing a cost-effective treatment that is high in demand in local as well as in the global market. The market in the Middle East and Africa is expected to account for the smallest share in the global Palliative care market due to the underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
The market has been segmented, by region, into the Americas, Europe, Asia Pacific, and the Middle East and Africa. The Global Palliative Care Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European Global Palliative Care Market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Global Palliative Care Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Palliative care market in the Middle East and Africa has been segmented into the Middle East and Africa.
Posted by at No comments:

Overactive Bladder Treatment Market Expected To Boost During 2019 To 2023

Market Scenario:
Overactive bladder is a condition that occurs in various diseases such as Parkinson's disease, multiple sclerosis, stroke, and others. Rise in prevalence of these diseases and rapid increase in the global geriatric population are inducing high demand for effective treatment of overactive bladder, which in turn is propelling the growth of the global overactive bladder treatment market. Increased marketing activities, availability of affordable treatments and development of innovative treatment procedures are also fueling the growth of the global overactive bladder treatment market. However, low penetration of treatment options in the healthcare sector and lack of awareness among the population of the underdeveloped countries are restricting the expansion of the global overactive bladder treatment market analysis during the assessment period.
The global overactive bladder treatment market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global overactive bladder treatment market is expected to register a CAGR of ~ 3.1% during the forecast period of 2018–2023.
Despite the drivers, lack of awareness in developing countries and undesired systemic effects of some current treatment options may hinder the growth of the market during the assessment period.
Company Profiles    
  • Astellas Pharma Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical
  • Allergan, Plc. 
  • Mylan N.V. 
  • Endo International Plc 
  • Hisamitsu Pharmaceutical Co., Inc.
  • Sanofi S. A.
  • Aurobindo Pharma Limited 
  • Johnson & Johnson
  • Intas Pharmaceuticals Ltd. 
  • Apotex Inc. 
  • Macleods Pharmaceuticals Ltd. 
  • Medtronic PLC
  • Cogentix Medical, Inc.
  • Others
Segmentation
The global overactive bladder treatment market is segmented on the basis of pharmacotherapy, non-pharmacological treatment, and disease.
On the basis of pharmacotherapy, the market is classified into anticholinergics, Botox, mirabegron, neurostimulation, and others. Further, anticholinergics are classified into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and others.
The global overactive bladder treatment market on the basis of non-pharmacological treatment is segmented into dietary and fluid modifications, behavioral therapy, pelvic floor muscle rehabilitation, and others.
On the basis of disease, the market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. Further, the neurogenic overactive bladder is segmented into the overactive bladder in Parkinson’s disease, the overactive bladder in stroke, the overactive bladder in spinal cord injury, and overactive bladder in other disorders.
Geographically, the global overactive bladder treatment market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The overactive bladder treatment market in the Americas is further segmented into North America and South America. North America is further classified as the US and Canada.
The overactive bladder treatment market in Europe is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe.
The overactive bladder treatment market in Asia-Pacific is segmented into Japan, China, India, Republic of Korea, Australia, and the rest of Asia-Pacific.
The overactive bladder treatment market in the Middle East and Africa is segmented into the Middle East and Africa.
Regional Market Summary
The global overactive bladder treatment market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. North America is anticipated to dominate the market in the Americas owing to the increasing geriatric population, growing occurrences of OAB, and the availability of numerous healthcare coverage systems such as Medicare.
Europe is anticipated to hold the second position in the global overactive bladder treatment market. It is estimated that the market growth in this region is attributed to the rising incidences of OAB and availability of reimbursement for certain treatment options. For instance, the UK’s National Institutes for Health and Care Excellence (NICE) provides reimbursement for the Botox therapy.
The overactive bladder treatment market in Asia-Pacific consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the growing prevalence of bladder overactivity, rising geriatric population, rising healthcare expenditure, and increasing awareness about overactive bladder condition.
The Middle East and Africa are likely to hold the least share in the global overactive bladder treatment market. In this region, the Middle East is expected to dominate owing to the rising healthcare expenditure and rising occurrences of neurological diseases, especially among the aged population.
Posted by at No comments:

Transthyretin Amyloidosis (ATTR) Market Segments, Opportunity, Growth And Forecast By End-Use Industry 2019

Market Scenario
The Transthyretin (TTR) amyloidosis market is expected to register a sturdy growth during the forecast period.  Transthyretin (TTR) amyloidosis is a medical condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in a body's organs and tissues. It generally affects peripheral neuropathic or autonomic neuropathy system and cardiac system. The cardiac form of Transthyretin (TTR) amyloidosis puts patients at the risk of arrhythmia, cardiomegaly, and orthostatic hypertension. The global ATTR market is likely to exhibit a robust growth during the forecast period due to the probability of rising number of ATTR therapeutic drugs launches, increasing African-American population as they are genetically susceptible to amyloidosis, increasing healthcare awareness among people, and rising average income of individuals. However, the growth of this market can be hindered by stringent regulatory policies, the high cost of ATTR drugs, incorrect diagnosis of ATTR disorders and limitations of clinical trials. Lack of knowledge about this condition and unavailability of advanced diagnostic methods in the middle-income countries are the major challenges to the market.
Top Market Players
  • Alnylam Pharmaceuticals
  • Pfizer
  • Merck
  • Ionis Pharmaceuticals Inc.
  • Corino Therapeutics Inc
  • Arcturus Therapeutics
  • Proclara Bioscience
Market Segmentation                                                                                                                          
Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
The global Transthyretin (TTR) amyloidosis market is segmented on the basis of disease type, treatment, gender, and end-user. Considering the type of disease, the market is segmented into Transthyretin (TTR) familial amyloid polyneuropathy, Transthyretin (TTR) familial amyloid cardiomyopathy, and others. On the basis of treatment, the market is segmented into small molecules treatment, RNAi therapy,  organ transplantation, and others. Small molecules treatment is further segmented into tafamidis and diflunisal. On gender basis, it is segmented into male and female. According to end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and others.
Regional Market Summary
Transthyretin Amyloidosis (ATTR) Market share and trends analysis on Regional basis, Americas dominates the market for Transthyretin (TTR) amyloidosis owing to the increasing prevalence of amyloidosis among adults and older population and rising geriatric population which is a major trigger factor for this disease. For instance, according to a report published by ASCO Journal in 2016 around 4,000 people developed amyloidosis each year in the United States. Thus, this rising patient pool is going to boost up the market growth during the forecast period. Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and rising use of technologically advanced medical diagnostic devices are likely to drive the market. The presence of pharmaceutical giants such as Pfizer, Merck, etc. also propels the market growth in this region.
Asia Pacific is expected to be the fastest growing market. According to a report published by the United Nations in 2015the number of older people aged 60 years or over in the world is predicted to grow by 56% between 2015 and 2030, out of which 66% of the older population would reside in the Asia Pacific region. This makes the region prone to Transthyretin (TTR) amyloidosis as chances of its prevalence increases with the increasing age. Owing to a huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, and availability favorable insurance and reimbursement policies, the market growth will be accelerated during the forecast period.  Moreover, key players such as Pfizer, Merck, etc. have been setting up their regional headquarters and manufacturing plants in countries such as Singapore, China, Japan, Korea, and Australia. Thus, the growth curve of the Transthyretin (TTR) amyloidosis market will see a positive trend of growth.
Europe is the second largest market and holds a healthy global Transthyretin (TTR) amyloidosis market share. The European market is expected to exhibit robust growth during the forecast period due to major driving factors such as availability of advanced treatment facilities, increasing healthcare expenditure along with growing need for better healthcare infrastructure, and government initiatives of healthcare reform.  It is reported that in the U.K., around 60 new cases of Transthyretin (TTR) amyloidosis are reported annually, and the age-specific incidence rate of it is between 5.1 and 12.8 per million per year. Additionally, established medical device market and capability of inhabitants to afford diagnostics are aiding the market growth. However, the inefficacy of treatment and wrong diagnosis are hampering the market growth of this region.
The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates and Saudi Arabia are the largest markets owing to the development of the healthcare industry and rising availability of specialty care centers. But the market might show a steady growth due to the genetical susceptibility of Africans for transthyretin amyloidosis and government initiatives to improve the quality of healthcare in this region.


Browse More Report Details @
Posted by at No comments:

Emphysema Market, Segments, Growth And Value Chain 2019

Synopsis of Global Emphysema Market
Emphysema, a lung disease is characterized by the shortness of breath, thereby, damaging the air sacs in the lungs. The disease leads to rupture and weakening of inner walls of the air sacs over the period. The disease involves the reduction in the surface area of the lungs which in turn reduces the amount of oxygen reaching the bloodstream. Hence, during exhalation, the alveoli do not function properly leaving the air trapped in the lungs, leaving no space for oxygen-rich air to enter the lungs. Emphysema and chronic bronchitis are together known as the Chronic Obstructive Pulmonary Disease (COPD). The patients suffering from emphysema also have chronic bronchitis. The major causes of emphysema are exposure to air pollutants, chemical fumes, and dust and smoking. The condition can be diagnosed through various tests such as imaging tests that include chest X-ray and CT scan and the lung function test.
The global emphysema market is mainly driven by the high prevalence of respiratory diseases such as chronic bronchitis, emphysema, and others and a huge demand for treatment including smoking cessation drugs and antibiotics. Additionally, the rising availability of diagnostic services for respiratory illness also fuels the growth of the market.
According to the World Health Organization, COPD affects nearly 210 million people which is attributed to the increasing population in urban areas across the globe and growing number of tobacco smokers.
The global emphysema market size is expected to grow at a CAGR of 6.1% during the forecast period.
Segments                                                                                                                        
The global emphysema market segments on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the market is segmented into centrilobular and panlobular emphysema.
On the basis of diagnosis, the market is segmented into imaging test, lung function test, and others. The imaging test is further segmented into chest X-ray and CT scan.
On the basis of treatment, the market is segmented into medications, therapy, and surgery. Medications are further segmented into smoking cessation drugs, bronchodilators, inhaled steroids, antibiotics, and leukotriene modifiers. Therapy is further segmented into pulmonary rehabilitation, nutrition therapy, gene therapy, and supplemental oxygen. Surgery is further segmented into lung volume reduction surgery, lung transplant, and bullectomy.
On the basis of end-user, the market is segmented into hospitals and clinics, surgical centers, and others.
Regional Analysis of the Global Emphysema Market               
The American emphysema market is segmented into two regions, namely, North America and South America. North America, being the largest market, is mainly driven by the increasing use of imaging test and lung function test for the diagnosis of the disease and huge population base diagnosed with COPD. Furthermore, the U.S. is the largest market in North America owing to the presence of large number of market players manufacturing medications for emphysema and increasing awareness about risk factors and cases of the disease. The American Lung Association stated that in the U.S., COPD is the fourth leading cause of deaths. Canada is expected to be the fastest growing market which is driven by the overall increasing demand for diagnostic medical devices with progress in the medical device sector. South America is expected to be the fastest growing market due to technologically advanced devices for diagnosis and the increasing demand for treatment options of respiratory diseases
The European emphysema market exhibits a positive growth with an increasing emphasis on the diagnosis of chronic respiratory conditions such as the COPD and asthma and increasing focus on research and development activities for the treatment of respiratory diseases. Germany and the U.K. are the major contributors to the growth of the market. Additionally, increasing expenditure in healthcare by major countries in Europe also accelerates the growth of the market.
Asia Pacific is expected to be the fastest growing market whose growth is attributed to a huge demand for lung function test and other diagnostic tests and the increasing focus on early diagnosis and treatment of lung diseases. Furthermore, other factors contributing to the growth of the market are lifestyle changes, the influence of western culture among the adults, and addiction to smoking. Additionally, rising environmental pollution and exposure to harmful chemicals also attribute to the growth of the market.
The Middle Eastern and African market for emphysema exhibits a steady rise with an increase in the number of healthcare facilities providing treatment for the chronic condition and the flourishing growth of medical device sector especially the diagnostic devices such as MRI and CT. In the African region, the awareness about COPD is increasing and is fueling the growth of the market.
Key Players in the Global Emphysema Market
Some of the key players in this market are Intrexon Corporation, Pulmonx Inc., Halozyme Therapeutics, Inc., Mariposa Health Limited, PneumRx, Uptake Medical Corporation, Icure Pharmaceuticals, Inc., Pfizer, Inc., BTG International’s, Olympus Corporation, Kamada Limited, Emphasys Medical, Inc. and others.
Posted by at No comments:
Subscribe to: Posts (Atom)